[{"id":"2af659b1-8c8a-446f-bb84-296e1e4e9b29","acronym":"","url":"https://clinicaltrials.gov/study/NCT00772486","created_at":"2021-01-18T02:55:09.387Z","updated_at":"2024-07-02T16:36:24.168Z","phase":"Phase 1b","brief_title":"A Phase Ib Study of ISF35 in Combination With Chemotherapy (FCR) in Subjects With Relapsed, Refractory, and/or 17p- CLL","source_id_and_acronym":"NCT00772486","lead_sponsor":"Memgen, LLC","biomarkers":" TP53 • CD20 • CD5 • FCER2","pipe":"","alterations":" ","tags":["TP53 • CD20 • CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cyclophosphamide • fludarabine IV • ISF35"],"overall_status":"Completed","enrollment":" Enrollment 13","initiation":"Initiation: 09/01/2008","start_date":" 09/01/2008","primary_txt":" Primary completion: 04/01/2011","primary_completion_date":" 04/01/2011","study_txt":" Completion: 04/01/2013","study_completion_date":" 04/01/2013","last_update_posted":"2021-09-22"},{"id":"f78899db-390d-4e53-8398-d00bc0607976","acronym":"","url":"https://clinicaltrials.gov/study/NCT00850057","created_at":"2021-01-18T03:14:10.483Z","updated_at":"2024-07-02T16:36:58.173Z","phase":"Phase 1","brief_title":"Pharmacodynamic (PD) Study of Intranodal Adenovirus-CD154 (Ad-ISF35) in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)","source_id_and_acronym":"NCT00850057","lead_sponsor":"University of California, San Diego","biomarkers":" CD20 • CD5 • CD40LG • FCER2","pipe":"","alterations":" ","tags":["CD20 • CD5 • CD40LG • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ISF35"],"overall_status":"Completed","enrollment":" Enrollment 16","initiation":"Initiation: 02/01/2006","start_date":" 02/01/2006","primary_txt":" Primary completion: 10/01/2009","primary_completion_date":" 10/01/2009","study_txt":" Completion: 10/01/2009","study_completion_date":" 10/01/2009","last_update_posted":"2019-07-12"},{"id":"b5aa8824-d949-43f9-9a6f-4c59b9290f50","acronym":"","url":"https://clinicaltrials.gov/study/NCT02719015","created_at":"2021-01-18T13:18:06.360Z","updated_at":"2024-07-02T16:37:16.084Z","phase":"Phase 1/2","brief_title":"Dose Escalation and Cohort Expansion of Safety and Tolerability Study of Intratumoral rAd.CD40L (ISF35) in Combination of Systemic Pembrolizumab in Patients With Refractory Metastatic Melanoma","source_id_and_acronym":"NCT02719015","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BRAF • CD40LG","pipe":" | ","alterations":" BRAF mutation","tags":["BRAF • CD40LG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • ISF35"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 03/01/2018","start_date":" 03/01/2018","primary_txt":" Primary completion: 03/01/2022","primary_completion_date":" 03/01/2022","study_txt":" Completion: 03/01/2022","study_completion_date":" 03/01/2022","last_update_posted":"2017-11-24"}]